

Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

Global Thematics strategy Concerns over inflation and the prospect of higher interest rates led to significant volatility

- 'Value' outpaced 'growth' on strong performance from banks and energy companies
- All themes declined but payments names were a bright spot in 'Connected Consumer'
- We selectively reduced some high duration positions in favour of quality companies

Amanda O'Toole
Portfolio Manager, Global Thematics Strategy

What's happening?

Global equity markets declined in January as concerns over inflation, higher interest rates and geopolitical tension in Eastern Europe led to a sharp increase in volatility. Value notably outperformed growth during the month as higher treasury yields and rising energy prices led to strong outperformance from banks and energy companies. Conversely, high growth companies derated as investors reassessed the value of future earnings in the context of higher interest rates going forward.

In the US, retail sales declined in December due to the impact of Omicron but other economic indicators held up well. The consumer price index increased 7% year-on-year and producer prices continued to climb in the face of sustained supply chain disruptions, rising materials costs and a tight labour market. In response, Fed Chair Jerome Powell suggested that a first rate rise is likely in March and refused to rule out a more aggressive sequence of increases thereafter.

Economic activity in Europe was resilient and low COVID hospitalisation rates encouraged several countries to lift restrictions. UK equities notably outperformed owing to its large weighting in financials and commodity stocks. The European Central Bank indicated that rates are unlikely to rise in 2022 despite rising inflation, which reached 5% year-on-year in December, while the Bank of England is expected to raise rates five times this year.

In China, the domestic economy showed further weakness with decelerating fixed asset investment and subdued retail sales; however, export numbers continue to be strong, rising 20.9% year-on-year in December.

Portfolio positioning and performance

The strategy underperformed the broader equity index (MSCI All Country World) in January as growth stocks remained under pressure during the month. All themes posted negative returns while 'Cleantech' and 'Automation' declined the most.





In 'Cleantech', shares in renewable energy solutions company Ameresco fell sharply. Investors reacted negatively to the postponement of its analyst day, which the company put down to covid concerns, while supply chain issues are expected to delay its solar projects. Despite this, we remain confident in the company's prospects given a diversified pipeline across energy infrastructure and renewable asset development.

Our position in semiconductor testing company Teradyne weighed most on 'Automation' after management provided weaker than expected guidance citing supply constraints and a drop in demand from one of its customers. While sales are likely to weaken over the coming quarters in response to key customer investment cycles, strong demand for chip testing, driven by increasing chip complexity, remains a notable tailwind for the company over the longer term.

'Ageing & Lifestyle' declined led by our position in Dexcom, which offers continuous glucose monitoring systems for diabetes management. The stock pulled back alongside other high growth names without any fundamental change in outlook. We expect the company to continue to deliver strong earnings growth supported by the launch of its latest G7 system in 2022 and opportunities in Type 2 diabetes further down the line.

On the positive side, 'Connected Consumer' returns were boosted by further gains from payments companies FIS, Global Payments and Visa. The group underperformed in 2021 but we expect their resilient earnings to prove more attractive in the context of slower growth more broadly in 2022 while further economic reopening and higher cross boarding payments should provide further upside.

We selectively reduced some high growth positions in favour of quality companies with lower duration risk which are well positioned to benefit from further reopening of the global economy. Examples include credit card issuer American Express and consumer goods company Unilever, while we also initiated a position in orthodontic technology company Align Technology which sold off with other growth names and provided an attractive buying opportunity.

Outlook

The recent market volatility is likely to persist as major central banks around the world embark upon an extended period of interest rate rises and quantitative tightening. The number of rate hikes expected in the US has markedly increased over recent months but we hasten to add it will take some time before we get back to pre-pandemic levels. Furthermore, economic activity remains robust and continued easing of covid related restrictions is supportive. While we expect growth to moderate in 2022, the trends underpinning the Evolving Economy continue to strengthen.

Solid industrial activity and strong order books for industrial robotics companies highlight the positive outlook for 'Automation' while ongoing supply chain disruptions only strengthen the case for automated solutions. 'Connected Consumer' companies have benefitted from an acceleration in the adoption of digital technologies since the pandemic and we expect this to continue as the economy forges ahead with its digital transformation. Further commitments from nations globally to dramatically lower emissions, combined with the recent volatility in energy prices, underlines the need for clean energy, storage and energy efficiency solutions which provides a strong tailwind for 'Cleantech' companies.

From a demographic standpoint, the ageing global population continues to create opportunities for 'Ageing & Lifestyle' companies which are positioned to benefit from long term changes in consumption patterns. The regulatory clampdown has weighed on sentiment in China but trends which include increasing wealth and financial inclusion, urbanisation and access to healthcare provide a positive backdrop for 'Transitioning Societies' more broadly.

We retain the view that high quality management teams, operating businesses with a sustainable competitive advantage in their markets and with the benefit of secular tailwinds are well placed to navigate the evolving economy. The strategy is therefore well positioned to benefit from the secular shifts we are witnessing globally.





No assurance can be given that the Global Thematics Strategy will be successful. Investors can lose some or all of their capital invested. The Global Thematics strategy is subject to risks including Equity; Emerging markets; Currency; Global investments; Investments in small and/or micro capitalisation universe; ESG.

Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in an European Union country by notification to its authority of supervision in accordance with European passport rules. In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English here). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The European online dispute resolution platform allows you to enter a complaint form (by clicking here) and informs you, depending on your jurisdiction, about your means of redress (by clicking here).

Issued in the U.K. by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.

In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as "professional investor" under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines or circulars which reference "professional investor" as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly.

MSCI: Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.